School of Pharmacy

Update from the Dean - Fall/Winter 2015

Strategic planning; Recently received research funding: cancer, Alzheimer's, HIV, type 2 diabetes (Kroetz, Keiser, Gross, Roy); Recent faculty publications: fibrosis, biofilms, gout (DeGrado, Yang, Giacomini); Collaborations and partnerships; Patient care: SB 493, scope of practice for California...

Major funding for The Kidney Project from NIBIB Quantum Program

The research journey toward building a fully functioning, surgically implantable artificial kidney as an alternative to kidney transplant and dialysis just took another step forward with the announcement of a $6 million grant to The Kidney Project, headquartered at the UCSF School of Pharmacy.

Yang study demonstrates simulator to study antibiotic dosing against biofilms

Nearly every human bacterial infection—including some of the most serious, life threatening, and costly to treat—can take the form of a biofilm, in which bacteria aggregate into structured communities that enclose themselves within a secreted slime.

Desai elected to the National Academy of Medicine

UCSF School of Pharmacy faculty member Tejal Desai, PhD, has been newly elected to the National Academy of Medicine (NAM), formerly known as the Institute of Medicine (IOM).

Fischbach joins project to generate drugs from bacterial genomes

Bacteria generate small molecules to fend off their fellow microbes. They also produce molecules that affect the response of host organisms—including humans—to their presence. Such molecules have been a major source of antibiotics, immunosuppressants, anti-cancer agents, and other drugs.

Benet to receive ISSX North American Scientific Achievement Award

UCSF School of Pharmacy faculty member Leslie Benet, PhD, has been named the 2015 recipient of the North American Scientific Achievement Award, presented by the International Society for the Study of Xenobiotics (ISSX).

UCSF-Amgen Symposium

The UCSF School of Pharmacy Industry Outreach Program presents a UCSF-Amgen Symposium.

This event will comprise two sessions:

Antibody Network partners with Celgene to develop cancer therapies

A new collaboration between Celgene Corp. and the Recombinant Antibody Network (RAN) will support the development of next-generation, antibody-based cancer therapies.

Pages